Cold Spring Harbor Laboratory
Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19
Publication
, Preprint
Demarest, JF; Kienle, M; Boytz, R; Ayres, M; Kim, EJ; Chung, D; Gandhi, V; Davey, R; Sykes, DB; Shohdy, N; Pottage, JC; Kumar, VS
March 31, 2022
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Demarest, J. F., Kienle, M., Boytz, R., Ayres, M., Kim, E. J., Chung, D., … Kumar, V. S. (2022). Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2022.03.30.486499
Demarest, James F., Maryline Kienle, RuthMabel Boytz, Mary Ayres, Eun Jung Kim, Donghoon Chung, Varsha Gandhi, et al. “Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.” Cold Spring Harbor Laboratory, March 31, 2022. https://doi.org/10.1101/2022.03.30.486499.
Demarest JF, Kienle M, Boytz R, Ayres M, Kim EJ, Chung D, et al. Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Cold Spring Harbor Laboratory. 2022.
Demarest, James F., et al. “Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.” Cold Spring Harbor Laboratory, 31 Mar. 2022. Crossref, doi:10.1101/2022.03.30.486499.
Demarest JF, Kienle M, Boytz R, Ayres M, Kim EJ, Chung D, Gandhi V, Davey R, Sykes DB, Shohdy N, Pottage JC, Kumar VS. Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Cold Spring Harbor Laboratory. 2022.